Liraglutide is a Glucagon-Like Peptide-1 Receptor (GLP-1R) agonist widely prescribed for the treatment of type 2 diabetes. Interestingly, anti-inflammatory properties of the GLP-1 pathway have been ...

Victoza (liraglutide) is a prescription drug used to help manage type 2 diabetes and reduce the risk of certain diabetes-related heart problems. Victoza is given as a daily injection under the skin.

This study provides valuable guidance for doctors and patients when choosing diabetes medications. It confirms that ...

Bengaluru: Biocon Limited, an innovation-led global biopharmaceutical company, has announced the launch of its GLP-1 peptide, ...

The primary focus was on GLP-1 agonists, including semaglutide and liraglutide, while a secondary focus was placed on officially approved alcohol use disorder medications, such as naltrexone ...

He was initiated on liraglutide injections with hopes to achieve better glycaemic control, but developed unrelenting nausea and vomiting during the third week of treatment. He presented to the ...

This launch follows the nod from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the ...

Biotechnology firm Biocon has announced the launch of its new product, Liraglutide, aimed at managing diabetes and obesity in the UK. This pivotal move was made public on Friday. The GLP-1 peptide, ...

KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that ...

Liraglutide was initiated within an hour of ... including blood glucose levels and the use of secondary preventive medications. The study’s primary endpoint was the proportion of new strokes ...